New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2013
16:04 EDTARRYArray BioPharma to initiate Phase 3 trial evaluating MEK162
Array BioPharma announced that it will initiate a global Phase 3 clinical trial in patients with recurrent low-grade serous ovarian cancer during the summer of 2013. The study, called MILO, will evaluate the efficacy and safety of MEK162 compared to standard chemotherapy treatments and is designed for worldwide regulatory submissions, including with the U.S. Food and Drug Administration and the European Medicines Agency. Array invented MEK162 and licensed worldwide rights to develop and commercialize the drug to Novartis in April 2010. The MILO study follows a recent announcement by Novartis detailing plans to initiate Phase 3 trials of MEK162 in both NRAS- and BRAF-mutant melanoma and will be covered as part of the Novartis/Array co-development agreement under which costs are capped annually and in total for Array.
News For ARRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
08:50 EDTARRYArray BioPharma participates in a conference call with JPMorgan
JPMorgan SMid Biotech Analyst Rama hosts a conference call with CEO Ron Squarer on June 5 at 1 pm.
May 28, 2015
06:04 EDTARRYArray BioPharma management to meet with Maxim
Meeting to be held in New York on May 28 hosted by Maxim.
May 19, 2015
07:28 EDTARRYUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use